Get the Stockscreener App
1.38
1.47%
0.02
After Hours:
1.39
0.01
+0.72%
Opko Health Inc stock is traded at $1.38, with a volume of 4.24M.
It is up +1.47% in the last 24 hours and down -0.36% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
See More
Previous Close:
$1.36
Open:
$1.35
24h Volume:
4.24M
Relative Volume:
0.95
Market Cap:
$1.09B
Revenue:
$711.41M
Net Income/Loss:
$-133.73M
P/E Ratio:
-7.2632
EPS:
-0.19
Net Cash Flow:
$-199.99M
1W Performance:
+9.52%
1M Performance:
-0.36%
6M Performance:
-9.80%
1Y Performance:
+0.73%
1-Day Range:
$1.35
$1.42
1-Week Range:
$1.28
$1.42
52-Week Range:
$1.19
$2.035
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Compare OPK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPK
Opko Health Inc
|
1.38 | 1.04B | 711.41M | -133.73M | -199.99M | -0.19 |
|
TMO
Thermo Fisher Scientific Inc
|
396.47 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
189.23 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
514.80 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
111.05 | 31.59B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
139.10 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-25-25 | Initiated | JP Morgan | Neutral |
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
BNP Paribas Financial Markets Sells 195,118 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Two Sigma Investments LP Boosts Stake in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Q2 EPS Estimates for OPKO Health Reduced by Zacks Research - MarketBeat
Quote - OPKO Health, Inc.
Millennium Management LLC Acquires 2,112,382 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Opko Health grants stock options, approves bonuses - Investing.com
Opko Health Grants Stock Options and Bonuses - TipRanks
Global Smart Inhalers Market to Observe Impressive Growth at a CAGR of ~21% by 2032 | DelveInsight - GlobeNewswire Inc.
OPKO Health (OPK) Rises with Promising Oncology Developments - GuruFocus
Down Syndrome Market: Epidemiology, Therapies, Companies, - openPR.com
What OPKO Health, Inc.'s (NASDAQ:OPK) P/S Is Not Telling You - simplywall.st
Hyperparathyroidism Treatment Market: Effective Treatment - openPR.com
Opko health outlines $675M-$685M revenue guidance for 2025 amid strategic initiatives - MSN
OPKO Health, Inc. (NASDAQ:OPK) Shares Acquired by Lazard Asset Management LLC - MarketBeat
Opko Completes Prolor Deal - Medical Product Outsourcing
Strong week for OPKO Health (NASDAQ:OPK) shareholders doesn't alleviate pain of three-year loss - Yahoo Finance
Esoteric Testing Market Set to Witness Significant Growth - openPR.com
OPKO Health to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Dimensional Fund Advisors LP Lowers Position in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Price T Rowe Associates Inc. MD Increases Stock Position in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Raymond James Financial Inc. Takes Position in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Renaissance Technologies LLC Sells 312,950 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Voya Investment Management LLC Sells 815,679 Shares of OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
OPKO Health, Inc. (NASDAQ:OPK) Shares Purchased by Barclays PLC - MarketBeat
Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright - MarketBeat
Entera Bio Announces First Quarter 2025 Financial Results and Business Updates - The Manila Times
Clinical Laboratory Tests Market Top PlayersARUP - openPR.com
Secondary Hyperparathyroidism Treatment Market Grows with Rising CKD Cases | Amgen, Sanofi, OPKO Health - openPR.com
Renaissance Technologies LLC Cuts Stake in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
Wells Fargo & Company MN Buys 29,738 Shares of OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Lowered to Sell Rating by StockNews.com - Defense World
Marshall Wace LLP Has $1.36 Million Position in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Invesco Ltd. Has $2.29 Million Stake in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Piper Sandler Keeps Their Buy Rating on Opko Health (OPK) - The Globe and Mail
OPKO Health, Inc. (NASDAQ:OPK) Q1 2025 Earnings Call Transcript - Insider Monkey
Weekly CEO Buys Highlight - GuruFocus
Labcorp Holdings Inc, BioReference Health, OPKO Health, Inc. - Olean Times Herald
OPKO Health’s Earnings Call: Mixed Sentiments and Strategic Moves - TipRanks
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 08 '25 |
Buy |
1.48 |
125,000 |
184,650 |
213,876,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Apr 01 '25 |
Buy |
1.65 |
100,000 |
164,850 |
213,751,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 28 '25 |
Buy |
1.70 |
150,000 |
254,385 |
213,651,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Mar 17 '25 |
Buy |
1.74 |
200,000 |
347,820 |
213,501,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Feb 28 '25 |
Buy |
1.71 |
67,434 |
115,312 |
213,301,448 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 28 '25 |
Buy |
1.47 |
47,537 |
70,060 |
213,234,014 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 17 '25 |
Buy |
1.47 |
150,000 |
220,425 |
213,186,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Jan 15 '25 |
Buy |
1.48 |
500,000 |
740,850 |
213,036,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 13 '24 |
Buy |
1.59 |
125,000 |
199,375 |
212,536,477 |
| FROST PHILLIP MD ET AL | CEO & Chairman |
Dec 11 '24 |
Buy |
1.56 |
500,000 |
781,050 |
212,411,477 |
0.61%
1.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):